Sandra D. Bakker

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Impact of age and comorbidity on survival in colorectal cancer.

Elmer E. van Eeghen, Sandra D. Bakker, Aart van Bochove et al. · PubMed · 2015 · 77 citations · Full text

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Karlijn de Joode, Daphne W. Dumoulin, Jolien Tol et al. · European Journal of Cancer · 2020 · 77 citations · Full text

Epidemiology, Cancer Epidemiology, Medicine +10

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations

Breast Oncology, Medicine, Primary Analysis +7

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study

Anna van der Voort, Fleur M. Louis, Mette S. van Ramshorst et al. · The Lancet Oncology · 2024 · 36 citations · Full text

Neoadjuvant Chemotherapy Duration, Breast Oncology, Medical Imaging +10